ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Monday, November 18, 2024

10:30AM-12:30PM
Abstract Number: 2231
Treatment Response over the First 6 Months in Newly Diagosed RA Patients by Pain, Anxiety, Depression & Fatigue (PADF) Symptom Clusters: Results from the Canadian Early Arthritis Cohort
RA – Diagnosis, Manifestations, & Outcomes Poster III
10:30AM-12:30PM
Abstract Number: 1845
Treg Expansion and IL-6 Induced STAT3 Phosphorylation in CD4+ T Cells Is a Biomarker of Disease Flare in Rheumatoid Arthritis
T Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster
10:30AM-12:30PM
Abstract Number: 2421
Trends in Glucocorticoid Use in Systemic Lupus Erythematosus in a Population-Based Inception Cohort from 1976 to 2018: The Lupus Midwest Network
SLE – Treatment Poster III
10:30AM-12:30PM
Abstract Number: 1877
Trends in Rheumatoid Arthritis Incidence, Prevalence, DALY and Death Rates (1991-2021) in the United States: A Comprehensive Analysis of State-Level Disparities
Epidemiology & Public Health Poster III
10:30AM-12:30PM
Abstract Number: 2167
Trust and Shared Decision-Making in Adolescents with Systemic Lupus Erythematosus: Findings from a Pilot Survey Design Study
Patient Outcomes, Preferences, & Attitudes Poster III
10:30AM-12:30PM
Abstract Number: 2168
Two Year Data on Quality of Life, Pain and Mobility Scores After Rituximab Treatment in the Preclinical Phase of Rheumatoid Arthritis
Patient Outcomes, Preferences, & Attitudes Poster III
10:30AM-12:30PM
Abstract Number: 2303
Type I Interferon Signature Drives Phenotypic Clusters of Sjögren’s Disease and Can Predict Systemic Evolution Among the “B-cell Active with Low Symptoms” Subgroup
Sjögren's Syndrome – Basic & Clinical Science Poster II
10:30AM-12:30PM
Abstract Number: 2073
Ultrasound Findings of Activity in Patients with Inflammatory Myopathies and Clinical and Laboratory Comparison
Muscle Biology, Myositis & Myopathies – Basic & Clinical Science Poster III
10:30AM-12:30PM
Abstract Number: 1955
Ultrasound for Screening of Rheumatoid Arthritis-Associated Interstitial Lung Disease: A Systematic Review and Meta Analysis
Imaging of Rheumatic Diseases Poster II
10:30AM-12:30PM
Abstract Number: 2290
Umbilical Cord-derived Mesenchymal Stem Cells Suppress Sjogren’s Syndrome Pathology
Sjögren's Syndrome – Basic & Clinical Science Poster II
10:30AM-12:30PM
Abstract Number: 1852
Uncovering a MAIT-Treg Axis in Skin UV Response: Implications for Photosensitive Reactions in Cutaneous Lupus Erythematosus
T Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster
10:30AM-12:30PM
Abstract Number: 2190
Uncovering Inborn Errors of Immunity in Pediatric Rheumatology
Pediatric Rheumatology – Clinical Poster III
10:30AM-12:30PM
Abstract Number: 1985
Underlying Autoimmune Disease Has Not Limited Immune Checkpoint Inhibitor Use or Increased Mortality Risk During Cancer Treatment of US Veterans
Immunological Complications of Medical Therapy Poster
10:30AM-12:30PM
Abstract Number: 1814
Understanding Monocyte Derived Macrophages in the Skin of SSc Patients Through Single Cell Analysis of Blister Fluid Immune Cell Populations
Systemic Sclerosis & Related Disorders – Basic Science Poster II
10:30AM-12:30PM
Abstract Number: 2079
Understanding Relapse Patterns in Anti-HMGCR Statin-induced IMNM: A Detailed Comparative Study
Muscle Biology, Myositis & Myopathies – Basic & Clinical Science Poster III
  • «Previous Page
  • 1
  • …
  • 48
  • 49
  • 50
  • 51
  • 52
  • …
  • 61
  • Next Page»
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology